{"id":1013,"date":"2022-07-25T19:06:44","date_gmt":"2022-07-25T19:06:44","guid":{"rendered":"http:\/\/events.marketsandmarkets.com\/blog\/?p=1013"},"modified":"2022-07-29T18:12:39","modified_gmt":"2022-07-29T18:12:39","slug":"speaker-spotlight-joseph-m-roig-4th-annual-next-gen-bioprocessing-conference","status":"publish","type":"post","link":"https:\/\/events.marketsandmarkets.com\/blognew\/speaker-spotlight-joseph-m-roig-4th-annual-next-gen-bioprocessing-conference\/","title":{"rendered":"Speaker Spotlight \u2013 \u2018Joseph M. Roig\u2019 : 4th Annual MarketsandMarkets Next-Gen Bioprocessing Conference!"},"content":{"rendered":"\n

Boston plays host to the 4th Annual MarketsandMarkets Next-Gen Bioprocessing Conference<\/a><\/strong> on the 20<\/strong>th<\/strong><\/sup> & 21<\/strong>st<\/strong><\/sup> of October 2022<\/strong> and we\u2019re literally counting down the days! With over 100+ attendees<\/strong> & in-depth case studies & keynote presentations from 15+ leading industry experts<\/strong>, the event promises to deliver a comprehensively enriching experience! <\/p>\n\n\n\n

As we keenly await to discover the speakers\u2019 ideas, findings\n& foresight into the future of topics surrounding cell culture &\nbioproduction, downstream processing & continuous biomanufacturing and cell\nand gene therapy analytics, here\u2019s a glimpse into what you can expect in\nBoston.<\/p>\n\n\n\n

As part of the build-up to the conference got to briefly chat with Joseph M. Roig<\/strong>, (Associate Technical Director at Apheresis & Global MSAT Cell Therapy Development and Operations at Bristol Myers Squibb)<\/em>. <\/strong>Here\u2019s what he had to say:<\/p>\n\n\n\n

<\/p>\n\n\n\n

1. What are the recent advances in cell and gene therapy and current challenges that need immediate attention<\/u> ?<\/strong><\/p>\n\n\n\n

Recent advances<\/u>: In-vivo<\/em> CAR T-cells induced by nanocarriers loaded with CAR genes and gene editing tools. This should circumvent most issues associated with autologous and allogeneic CAR T-cell products.<\/p>\n\n\n\n

Current\nchallenges: CAR T-cell manufacturing failure rate related to sub-optimal CD3+\ncells (senescent, exhausted) collected from the patient. Most current CAR\nT-cell therapies have been approved as a third line treatment, so by the time\nCD3+ cells are collected from the patient, the patient has already received\nvery aggressive treatments that negatively impact the health of the collected\nCD3+ cells, making CAR T-cell manufacturing difficult or even impossible.<\/p>\n\n\n\n


2. What will be the key takeaways from your presentation which will help in expanding the knowledge base of the attendees<\/u> ?<\/strong><\/p>\n\n\n\n